announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the Agency’s Web site at http://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to the appropriate advisory committee meeting link, or call the advisory committee information line to learn about possible modifications before coming to the meeting.

Agenda: On January 14, 2016, the committee will meet by teleconference. In open session, the committee will hear updates of the research program in the Laboratory of Method Development, Division of Viral Products, Center for Biologics Evaluation and Research, FDA.

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA’s Web site after the meeting. Background material is available at http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee meeting link.

Procedure: On January 14, 2016, from 1 p.m. to 3:35 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before January 7, 2016. Oral presentations from the public will be scheduled between approximately 2:35 p.m. and 3:35 p.m. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before December 29, 2015. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by December 30, 2015.

Closed Committee Deliberations: On January 14, 2016, from 3:35 p.m. to 5 p.m., the meeting will be closed to permit discussion where disclosure would constitute a clearly unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)). The Committee will discuss the report of the intramural research program and make recommendations regarding personnel staffing decisions.

Persons attending FDA’s advisory committee meetings are advised that the Agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact Sujata Vijh at least 7 days in advance of the meeting.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: November 20, 2015.

Jill Hartzler Warner,
Associate Commissioner for Special Medical Programs.

BILLING CODE 4164-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Service Administration

Advisory Committee on Interdisciplinary, Community-Based Linkages; Notice of Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), notice is hereby given of the following meeting:

Name: Advisory Committee on Interdisciplinary, Community-Based Linkages (ACICBL).

Dates and Times: December 15, 2015 (9:30 a.m.—4:00 p.m.).

Place: Conference Call/Webinar Format.

Status: The meeting will be open to the public.

Purpose: The ACICBL provides advice and recommendations to the Secretary of the Department of Health and Human Services (Secretary) concerning policy, program development, and other matters of significance related to interdisciplinary, community-based training grant programs authorized under sections 750–759, Title VII, Part D of the Public Health Service Act, as amended by the Affordable Care Act. The following sections are included under this Part: 751—Area Health Education Centers; 752—Continuing Education Support for Health Professionals Serving in Underserved Communities; 753—Geriatrics Workforce Enhancement; 754—Quentin N. Burdick Program for Rural Interdisciplinary Training; 755—Allied Health and Other Disciplines; 756—Mental and Behavioral Health Education and Training; and 759—Program for Education and Training in Pain Care.

The members of the ACICBL will select a topic for the legislatively mandated 16th report. They will also finalize their discussion of the legislatively mandated 15th Annual Report to the Secretary of Health and Human Services and Congress. In the 15th Annual Report they will make recommendations for Title VII, Part D programs, performance measures, and appropriation levels.

Agenda: The ACICBL agenda will be available 2 days prior to the meeting on the HRSA Web site at http://www.hrsa.gov/advisorycommittees/hprradvisory/acicbl/index.html.

SUPPLEMENTARY INFORMATION: Requests to make oral comments or provide written comments to the ACICBL should be sent to Dr. Joan Weiss, Designated Federal Official, using the address and phone number below. Individuals who plan to participate on the conference call and webinar should notify Dr. Weiss at least 3 days prior to the meeting, using the address and phone number below. Members of the public will have the opportunity to provide comments. Interested parties should refer to the meeting subject as the HRSA Advisory Committee on Interdisciplinary, Community-Based Linkages.

• The conference call-in number is 1–800–619–2521. The passcode is: 9271697.

• The webinar link is https://hrsa.connectsolutions.com/acicbl-meeting/.

Contact: Anyone requesting information regarding the ACICBL should contact Dr. Joan Weiss, Designated Federal Official within the Bureau of Health Workforce, Health Resources and Services Administration, in one of three ways: (1) Send a request to the following address: Dr. Joan Weiss, Designated Federal Official, Bureau of
Health Workforce, Health Resources and Services Administration. Room 12C–05, 5600 Fishers Lane, Rockville, Maryland 20857; (2) call (301) 443–0430; or (3) send an email to jweiss@hrsa.gov.

Jackie Painter, Director, Division of the Executive Secretariat.

If you have questions about this information collection, call non-toll-free number 919–541–9690, write to Chief, Epidemiology Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, 5600 Fishers Lane, Rockville, Maryland 20857; (2) call (301) 443–0430; or (3) email to sandler@niehs.nih.gov.

To obtain a copy of the paper submitted to the Office of Management and Budget (OMB) for review and approval.

To submit comments in writing, or request further information:

I NEED AND USE OF INFORMATION:
The purpose of this information collection is to request new components as part of the ongoing Study of Biomarkers of Exposures and Effects in Agriculture (BEEA), as well as continue and complete phase IV (2013–2016) of the Agricultural Health Study (AHS) and continue buccal cell collection. Phase IV will continue to update the occupational and environmental exposure information as well as medical history information for licensed pesticide applicators and their spouses enrolled in the AHS. The new BEEA components are a control respondent group, and a smartphone application (app), along with new sample collection (buccal cell and air monitoring samples). The new components will use similar procedures to ones already employed on the BEEA study, as well as other NCI studies. The primary objectives of the study are to determine the health effects resulting from occupational and environmental exposures in the agricultural environment. Secondary objectives include evaluating biological markers that may be associated with agricultural exposures and risk of certain types of cancer. Phase IV questionnaire data are collected by using self-administered computer assisted web survey (CAWI); self-administered paper-and-pen (Paper/pen); or an interviewer administered computer assisted telephone interview (CATI) and in-person interview (CAPI) systems for telephone screeners and home visit interviews, respectively. Some respondents are also asked to participate in the collection of biospecimens and environmental samples, including blood, urine, buccal cells (loose cells from the respondent’s mouth), and vacuum dust. The findings will provide valuable information concerning the potential link between agricultural exposures and cancer and other chronic diseases among Agricultural Health Study cohort members, and this information may be generalized to the entire agricultural community.

ESTIMATED DATES:

Comment Due Date: Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication.

Proposed Collection: The Agricultural Health Study: A Prospective Cohort Study of Cancer and Other Disease Among Men and Women in Agriculture (BEEA), as well as medical history information for licensed pesticide applicators and their spouses enrolled in the AHS. The new BEEA components are a control respondent group, and a smartphone application (app), along with new sample collection (buccal cell and air monitoring samples). The new components will use similar procedures to ones already employed on the BEEA study, as well as other NCI studies. The primary objectives of the study are to determine the health effects resulting from occupational and environmental exposures in the agricultural environment. Secondary objectives include evaluating biological markers that may be associated with agricultural exposures and risk of certain types of cancer. Phase IV questionnaire data are collected by using self-administered computer assisted web survey (CAWI); self-administered paper-and-pen (Paper/pen); or an interviewer administered computer assisted telephone interview (CATI) and in-person interview (CAPI) systems for telephone screeners and home visit interviews, respectively. Some respondents are also asked to participate in the collection of biospecimens and environmental samples, including blood, urine, buccal cells (loose cells from the respondent’s mouth), and vacuum dust. The findings will provide valuable information concerning the potential link between agricultural exposures and cancer and other chronic diseases among Agricultural Health Study cohort members, and this information may be generalized to the entire agricultural community.

ESTIMATED ANNUALIZED BURDEN HOURS

<table>
<thead>
<tr>
<th>Type of respondent</th>
<th>Form name</th>
<th>Estimated annual number of respondents</th>
<th>Number of responses per respondent</th>
<th>Average time per response (in hours)</th>
<th>Total annual burden hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Private and Commercial Applicators and Spouses.</td>
<td>Reminder, Missing, and Damaged Scripts for Buccal Cell.</td>
<td>100</td>
<td>1</td>
<td>5/60</td>
<td>8</td>
</tr>
<tr>
<td>Private Applicators</td>
<td>BEEA CATI Eligibility Script</td>
<td>480</td>
<td>1</td>
<td>20/60</td>
<td>160</td>
</tr>
<tr>
<td>Private Applicators</td>
<td>Mailed Consent, Pre-Visit Show Card, and Paper/Pen Dust Questionnaire.</td>
<td>160</td>
<td>1</td>
<td>20/60</td>
<td>53</td>
</tr>
<tr>
<td>Private Applicators</td>
<td>BEEA Home Visit CAPI, Blood, Buccal cell, Urine &amp; Dust.</td>
<td>160</td>
<td>1</td>
<td>90/60</td>
<td>240</td>
</tr>
<tr>
<td>Private Applicators</td>
<td>BEEA Pre-Visit Scripts</td>
<td>20</td>
<td>3</td>
<td>5/60</td>
<td>5</td>
</tr>
<tr>
<td>Private Applicators</td>
<td>BEEA Home Visit CAPI, Blood, Buccal cell, Urine, &amp; Dust x 3.</td>
<td>20</td>
<td>3</td>
<td>90/60</td>
<td>90</td>
</tr>
<tr>
<td>Private Applicators</td>
<td>BEEA Mailed Consents (Home Visit &amp; Farm Visit), Pre-Visit Show Card, and Paper/Pen Dust Questionnaire.</td>
<td>16</td>
<td>1</td>
<td>25/60</td>
<td>7</td>
</tr>
<tr>
<td>Private Applicators</td>
<td>BEEA Home Visit CAPI, Blood, Urine, Buccal cell &amp; Dust x 2.</td>
<td>16</td>
<td>2</td>
<td>90/60</td>
<td>16</td>
</tr>
<tr>
<td>Controls</td>
<td>BEEA CATI Control Eligibility Script</td>
<td>215</td>
<td>1</td>
<td>20/60</td>
<td>72</td>
</tr>
</tbody>
</table>